TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15704046

Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg orally for 14 days) plus calcium (500 mg daily) and vitamin D (400 IU daily) for 76 days, repeated 8 times over 24 months
Number of subjects: 154

Group type: COMPARATOR
Intervention: Calcium (500 mg daily) and vitamin D (400 IU daily) for 76 days, repeated 8 times over 24 months without etidronate
Number of subjects: 154
Study: 12081675

Group type: EXPERIMENTAL
Intervention: 100 U BTX‐A (50 U/ml/axilla)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10403160

Group type: EXPERIMENTAL
Intervention: Antidepressant medications
Number of subjects: 50
Study: 8648964

Group type: EXPERIMENTAL
Intervention: Small dose kaliposol + etomidate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 80
Study: 8263318

Group type: EXPERIMENTAL
Intervention: Sertraline (mean daily dose 72 mg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fluoxetine (mean daily dose 28 mg)
Number of subjects: 108
Study: 4072939

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 or 360 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 or 100 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of Diltiazem and Hydrochlorothiazide
Number of subjects: 20
Study: 30843453

Group type: EXPERIMENTAL
Intervention: 20 mg THA
Number of subjects: 159

Group type: COMPARATOR
Intervention: 40 mg THA
Number of subjects: 159
Study: 29465273

Group type: EXPERIMENTAL
Intervention: Telephone Intervention-Problem Solving (TIPS) for nine months
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) antipsychotic delivery
Number of subjects: 87
Study: 27833863

Group type: EXPERIMENTAL
Intervention: Intubation for 12 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intubation for less than 12 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intubation for more than 12 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intubation for more than 18 months
Number of subjects: 120
Study: 24743584

Group type: EXPERIMENTAL
Intervention: Methoxyflurane via Penthrox inhaler
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 22755270

Group type: EXPERIMENTAL
Intervention: 0.8 ml of 4 mg 0.5% hyperbaric bupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.3-ml solution of 4 mg 0.5% hyperbaric bupivacaine + 25 microg of fentanyl
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.1-ml solution of 3 mg 0.5% hyperbaric bupivacaine + 25 microg of fentanyl
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no opioid)
Number of subjects: 45
Study: 19577885

Group type: EXPERIMENTAL
Intervention: Posterolateral approach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Direct-lateral approach
Number of subjects: 60
Study: 17001749

Group type: EXPERIMENTAL
Intervention: Patient self-report after six and twelve months
Number of subjects: 0

Group type: COMPARATOR
Intervention: GP records by independent investigators
Number of subjects: 0
Study: 16199701

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 115

Group type: COMPARATOR
Intervention: Nonanesthetic lubricant (control)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups (lidocaine and control)
Number of subjects: 115
Study: 11818036

Group type: EXPERIMENTAL
Intervention: 3.5 hour workshop on Evidence Based Medicine (EBM)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Workshop on bioethics (control intervention)
Number of subjects: 83
Study: 10367928

Group type: EXPERIMENTAL
Intervention: Hot-water irrigation (HWI)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Tamponade treatment
Number of subjects: 122
Study: 8680064

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 2076247

Group type: EXPERIMENTAL
Intervention: Sorbitol gum (Trident) chewed for 10 minutes after ingestion of snacks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sucrose-containing snacks (chocolate bar, cream-filled cupcakes, cream-filled sandwich cookie, cherry pie, raisins)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Starch-containing snacks (oat cereal, granola bars, pretzels, potato chips, corn chips)
Number of subjects: 5
Study: 381221

Group type: EXPERIMENTAL
Intervention: Tolmetin 200 mg (T 200)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paracetamol 400 mg (P 400)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tolmetin 150 mg plus Paracetamol 300 mg (T 150 + P 300)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tolmetin 100 mg plus Paracetamol 400 mg (T 100 + P 400)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30404563

Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (300 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (wheat starch)
Number of subjects: 60
Study: 30910240

Group type: EXPERIMENTAL
Intervention: Verified hip fracture (HF)
Number of subjects: 449
Study: 28401850

Group type: EXPERIMENTAL
Intervention: Mothering From the Inside Out (MIO)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Parent Education (PE)
Number of subjects: 87
Study: 26073532

Group type: EXPERIMENTAL
Intervention: UFT/leucovorin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 67
Study: 23670794

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil (EVOO)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 522

Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 522
Study: 21885886

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous intensity exercise intervention for 6 months, home-based, telephone-administered
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 50
Study: 19793239

Group type: EXPERIMENTAL
Intervention: Focus group intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 17236781

Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (MST)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Posterolateral thoracotomy (PLT)
Number of subjects: 100
Study: 15126737

Group type: EXPERIMENTAL
Intervention: Traditional (blind) transesophageal echocardiography
Number of subjects: 159

Group type: COMPARATOR
Intervention: Optical transesophageal echocardiography
Number of subjects: 159
Study: 11254756

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day for 30 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) (600 mg/day for 30 days after a washout period)
Number of subjects: 6
Study: 9628403

Group type: EXPERIMENTAL
Intervention: Increased peak movement velocity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Presence of external viscous loads
Number of subjects: 5
Study: 8200250

Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg thrice daily for seven days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Metronidazole vs Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 13
Study: 3295163

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 31785838

Group type: EXPERIMENTAL
Intervention: Genetically predicted one standard deviation increase of serum 25-hydroxyvitamin D (S-25OHD) concentrations
Number of subjects: 35052

Group type: COMPARATOR
Intervention: Control group (individuals without ALS)
Number of subjects: 35052
Study: 30082180

Group type: EXPERIMENTAL
Intervention: 7° reverse Trendelenburg position (RTP)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 125
Study: 28851800

Group type: EXPERIMENTAL
Intervention: Chinese version of the Severe Respiratory Insufficiency (SRI) questionnaire
Number of subjects: 149
Study: 25798727

Group type: EXPERIMENTAL
Intervention: Positively framed message
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Negatively framed message
Number of subjects: 76
Study: 23176776

Group type: EXPERIMENTAL
Intervention: Patients with systemic hypertension
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 17
Study: 20869152

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 25 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 50 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 100 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 19594501

Group type: EXPERIMENTAL
Intervention: Verapamil (n = 10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined verapamil/lithium (Phase 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Continued-lithium (n = 8)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lithium monotherapy (Phase 2)
Number of subjects: 45
Study: 17285947

Group type: EXPERIMENTAL
Intervention: Breast brachytherapy
Number of subjects: 25
Study: 12807406

Group type: EXPERIMENTAL
Intervention: Affiliation goal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unsuccessful affiliation attempts
Number of subjects: 0
Study: 11374850

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (AFCAPS/TexCAPS)
Number of subjects: 0
Study: 8843920

Group type: EXPERIMENTAL
Intervention: Blue-on-yellow perimetry using an argon laser (lambda = 458 nm) with a low background
Number of subjects: 5

Group type: COMPARATOR
Intervention: Red-on-red perimetry using a HeNe laser (lambda = 633 nm)
Number of subjects: 5
Study: 1377484

Group type: EXPERIMENTAL
Intervention: F2 regimen (17 Gy in two fractions of 8.5 Gy 1 week apart)
Number of subjects: 233

Group type: COMPARATOR
Intervention: F1 regimen (single fraction of 10 Gy)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: F2 regimen
Number of subjects: 233

Group type: COMPARATOR
Intervention: F1 regimen
Number of subjects: 233
Study: 6085377

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10‐40 mg/day)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Hydralazine (50‐200 mg/day)
Number of subjects: 105
Study: 31427869

Group type: EXPERIMENTAL
Intervention: BFR training with protein (collagen hydrolysate) supplementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BFR training with placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group without training, but with protein supplementation
Number of subjects: 30
Study: 29159774

Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch (1.25 mg/24 h, 1.25 mg/48 h, 2.5 mg/48 h, 2.5 mg/72 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rasagiline oral tablet (1 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch (1.25 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch (2.5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch (1.25-2.5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rasagiline transdermal patch
Number of subjects: 15
Study: 26841365

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplements (800 IU/day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 25138611

Group type: EXPERIMENTAL
Intervention: Biodegradable fixation system (Inion CPS)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Titanium fixation system (KLS Martin)
Number of subjects: 230
Study: 22296077

Group type: EXPERIMENTAL
Intervention: GAD‐alum (four doses)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: GAD‐alum (two doses) followed by placebo (two doses)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo (four doses)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: GAD‐alum (any dosage)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo (any dosage)
Number of subjects: 334
Study: 20618359

Group type: EXPERIMENTAL
Intervention: Maximal exercise test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Submaximal exercise test
Number of subjects: 12

Group type: COMPARATOR
Intervention: Maximal and submaximal exercises
Number of subjects: 12
Study: 18240797

Group type: EXPERIMENTAL
Intervention: Topical gel composed of 18% potassium complex, 10% dimethylisosorbide, and 72% aqueous hydroxyethyl cellulose gel applied to the facial skin over painful areas.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical gel application as a first-step procedure before definitive diagnosis and treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical gel application.
Number of subjects: 0
Study: 15900603

Group type: EXPERIMENTAL
Intervention: Imatinib treatment followed by resection of residual disease
Number of subjects: 90

Group type: COMPARATOR
Intervention: Imatinib treatment
Number of subjects: 90
Study: 12463482

Group type: EXPERIMENTAL
Intervention: CD8+ depleted DLI
Number of subjects: 18

Group type: COMPARATOR
Intervention: Unselected DLI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 10519615

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice a day) for > or = 5 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8522669

Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.015 mg kg‐1 injected within 5 min to 9 patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (9 patients)
Number of subjects: 18
Study: 1720527

Group type: EXPERIMENTAL
Intervention: MODE (30 micrograms/kg/min x 15 min, then 7.5 micrograms/kg/min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MODE (at a mean concentration of 774 +/- 229 ng/ml)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MODE
Number of subjects: 8
Study: 6758935

Group type: EXPERIMENTAL
Intervention: Intravenous tiapamil (1 mg/kg loading dose followed by 50 micrograms/kg/min for 2 hours)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral tiapamil (approximately 6 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 6
Study: 30145623

Group type: EXPERIMENTAL
Intervention: Optimized intervention (IO and GO)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-optimized intervention (NO)
Number of subjects: 52
Study: 29649012

Group type: EXPERIMENTAL
Intervention: Isometric exercise program
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Isotonic exercise program
Number of subjects: 29
Study: 27396815

Group type: EXPERIMENTAL
Intervention: Programmed sports therapy (PST)
Number of subjects: 64
Study: 24743431

Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) 135 mg plus atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) plus atorvastatin
Number of subjects: 0
Study: 22052941

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 19345869

Group type: EXPERIMENTAL
Intervention: FasT-Fix suture devices
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2-0 polydioxane (PDS) sutures
Number of subjects: 10
Study: 17244773

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15151330

Group type: EXPERIMENTAL
Intervention: Colgate Simply‐White Whitening Gel (5.9% hydrogen peroxide)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study: 11703565

Group type: EXPERIMENTAL
Intervention: Blue/green LED
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Light box
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: White LED
Number of subjects: 66

Group type: COMPARATOR
Intervention: No light control group
Number of subjects: 66
Study: 10987677

Group type: EXPERIMENTAL
Intervention: Growth hormone substitution (2 IU/m2) for 12 months
Number of subjects: 25
Study: 7992358

Group type: EXPERIMENTAL
Intervention: Towne strain attenuated CMV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2572266

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0
Study: 49737

Group type: EXPERIMENTAL
Intervention: Yoga relaxation methods with bio-feedback
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo therapy (general relaxation)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Yoga relaxation methods with bio-feedback (after control group trained)
Number of subjects: 34
Study: 31171074

Group type: COMPARATOR
Intervention: Pulpectomy
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS) pulpotomy
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (SH) pulpotomy
Number of subjects: 830
Study: 27481122

Group type: EXPERIMENTAL
Intervention: Nutritional interventions
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both nutritional interventions and physical exercise
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Biological outcome variables
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Muscle mass, muscle strength, and physical performance
Number of subjects: 123
Study: 26342653

Group type: EXPERIMENTAL
Intervention: Persistent dyssynchrony after CRT-D
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: New dyssynchrony after CRT-D
Number of subjects: 151
Study: 23760914

Group type: EXPERIMENTAL
Intervention: 2‐micron continuous‐wave laser resection (2‐µm laser)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional monopolar transurethral resection of bladder tumour (TURBT)
Number of subjects: 120
Study: 22093054

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) filler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) filler with nonablative infrared (IR) device
Number of subjects: 12
Study: 17586581

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16437283

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 157
Study: 12766641

Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg intravenous)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Norepinephrine infusion
Number of subjects: 20
Study: 11287028

Group type: EXPERIMENTAL
Intervention: CEE+MPA regimens
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CEE+MPA and Tibolone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CEE+MPA, Tibolone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 60
Study: 9291200

Group type: COMPARATOR
Intervention: Usual-protein diet (1.3 g/kg/day)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.58 g/kg/day)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (0.28 g/kg/day) supplemented with a ketoacid-amino acid mixture (0.28 g/kg/day)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Low-protein and very-low-protein diets combined
Number of subjects: 840
Study: 8340295

Group type: EXPERIMENTAL
Intervention: Sleep deprivation for 36 hours
Number of subjects: 17
Study: 3543705

Group type: EXPERIMENTAL
Intervention: Oral colistin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 145

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Prophylactic use of antibiotics
Number of subjects: 145
Study: 30968632

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus GG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 150
Study: 27838144

Group type: EXPERIMENTAL
Intervention: In-Home Cognitive Behavioral Therapy (IH-CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study: 26264735

Group type: EXPERIMENTAL
Intervention: Web-based CBT with protocol driven feedback
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Web-based CBT with support on demand
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Web-based CBT formats
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Web-based CBT interventions
Number of subjects: 240
Study: 22858150

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21122063

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of pioglitazone 15mg/metformin 850mg twice daily (bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin 850mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDC and pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDC
Number of subjects: 0
Study: 18209255

Group type: EXPERIMENTAL
Intervention: Class-based exercise program (CB)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Home-based exercise program (HB)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (HB)
Number of subjects: 172
Study: 17205827

Group type: EXPERIMENTAL
Intervention: Huangbai Liquid (HL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: famciclovir
Number of subjects: 27
Study: 15301640

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral treatment (CBT)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 549
Study: 10886123

Group type: EXPERIMENTAL
Intervention: Oestradiol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Medroxy‐progesterone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8